Ibrexafungerp
Back to searchMolecule Structure
Scientific Name
Ibrexafungerp
Description of the Drug
Ibrexafungerp is a triterpene antifungal indicated in the treatment of vulvovaginal candidiasis and prevention of recurrent vulvovaginal candidiasis in post-menarchal patients.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12471
http://www.drugbank.ca/drugs/DB12471
Brand Name(s)
Not Available
Company Owner(s)
Scynexis Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| 1,3-beta-glucan synthase | SINGLE PROTEIN | INHIBITOR | CHEMBL2364674 |
| 1,3-beta-glucan synthase | SINGLE PROTEIN | INHIBITOR | CHEMBL2364673 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL3479266 | |
| Human Metabolome Database | HMDB0304839 | |
| DrugBank | DB12471 | |
| PubChem: Thomson Pharma | 99311277 | |
| PubChem | 46871657 | |
| DrugCentral | 5461 | 5462 |
| PubChem: Drugs of the Future | 123055447 |
